Fleming Special Precautions

Fleming Oral suspension contains aspartame therefore care should be taken in phenylketonuria.
Fleming tablets contain small amounts of potassium.
Changes in liver function tests have been observed in some patients receiving co-amoxiclav. The clinical significance of these changes is uncertain but co-amoxiclav should be used with caution in patients with evidence of hepatic dysfunction. Cholestatic jaundice, which may be severe, but is usually reversible, has been reported rarely. Signs and symptoms may not become apparent for up to six weeks after treatment has ceased. In patients with moderate or severe renal impairment co-amoxiclav dosage should be adjusted as recommended in Dosage & Administration. Serious and occasionally fatal hypersensitivity (anaphylactoid) reactions have been reported in patients on penicillin therapy. These reactions are more likely to occur in individuals with a history of penicillin hypersensitivity. Erythematous rashes have been associated with glandular fever in patients receiving amoxicillin. Co-amoxiclav should be avoided if glandular fever is suspected. Prolonged use may also occasionally result in overgrowth of non-susceptible organisms.